Finasteride (Proscar 5 mg for BPH; Propecia 1 mg for hair loss) is a type II 5-alpha reductase inhibitor that blocks the conversion of testosterone to the more potent DHT, gradually shrinking the prostate or slowing androgenetic alopecia. Common side effects include decreased libido, erectile dysfunction, and reduced ejaculatory volume. A critical note: finasteride suppresses PSA levels by approximately 50% — clinicians must double the measured PSA value to correctly interpret prostate cancer screening results. The drug is absolutely contraindicated in pregnancy due to teratogenic effects on male fetal development.
Finasteride
Uses & FDA Indications
Finasteride is FDA-approved under two brand names for two distinct indications at different doses. Proscar (5 mg) is approved for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Unlike tamsulosin, which relaxes smooth muscle to relieve obstruction dynamically, finasteride actually shrinks prostate tissue over time by removing the hormonal stimulus (DHT) driving prostate growth.
Propecia (1 mg) is FDA-approved for the treatment of androgenetic alopecia (male pattern baldness) in men. It slows or halts the DHT-driven miniaturization of hair follicles and, in many patients, promotes visible regrowth — particularly at the vertex (crown) of the scalp. It is not approved for women, and the clinical benefit in women is uncertain.
Off-label uses include transgender hormone therapy (as an antiandrogen component in feminizing regimens), and finasteride has been investigated in combination with minoxidil for enhanced hair loss treatment.
The two formulations serve different indications at different doses: Proscar 5 mg for BPH (prostate enlargement) and Propecia 1 mg for male pattern hair loss. Both contain the same active ingredient. Some patients prescribed Propecia purchase Proscar and cut tablets to reduce cost — this practice eliminates the film coating that protects others from teratogenic skin exposure and is not recommended without specific guidance.
How It Works
Testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is a more potent androgen than testosterone — it binds the androgen receptor with approximately five times greater affinity. DHT is the primary hormonal driver of both prostate growth and androgenetic alopecia. It signals prostate cells to proliferate and causes scalp hair follicles to progressively miniaturize through a process called follicular regression.
Finasteride selectively inhibits the type II isoform of 5-alpha reductase, which is the predominant isoform in the prostate and hair follicles. By blocking this enzyme, finasteride reduces serum DHT levels by approximately 65–70% and intraprostatic DHT by approximately 85–90%. The result in BPH is gradual prostate shrinkage (roughly 20–25% volume reduction over 6–12 months), improved urinary flow, and reduced risk of acute urinary retention. In androgenetic alopecia, reduced DHT exposure halts follicular miniaturization and, in many patients, partially reverses it.
Testosterone levels actually increase modestly during finasteride treatment, since less is being converted to DHT. This hormonal shift is generally well tolerated but contributes to the complex androgenic balance that finasteride disrupts.
PSA INTERFERENCE — CRITICAL: Finasteride reduces serum PSA by approximately 50% after 6 months of use. Clinicians interpreting PSA results in finasteride-treated patients must double the measured PSA value to estimate the unmedicated equivalent. Failure to account for this can mask a significant PSA elevation and delay prostate cancer detection. All PSA results should be interpreted in the context of finasteride use.
Side Effects
Sexual Side Effects
- Decreased libido (reduced sex drive) — most commonly reported sexual adverse effect; occurs in approximately 3–6% of patients in clinical trials, though real-world reporting rates may be higher
- Erectile dysfunction — reported in 3–5% of clinical trial participants; may be related to DHT's role in penile tissue health and nitric oxide signaling
- Decreased ejaculatory volume — reduced seminal fluid production; related to prostate and seminal vesicle DHT reduction
- Ejaculatory dysfunction — abnormal or absent ejaculation
Other Common Side Effects
- Breast enlargement or tenderness (gynecomastia) — occurs in approximately 0.4–2.8% of patients; the altered testosterone-to-estrogen ratio may contribute
- Testicular pain — reported less commonly
- Skin rash, pruritus, urticaria — hypersensitivity reactions
Post-Finasteride Syndrome (Persistent Effects)
A subset of patients report that sexual dysfunction, cognitive symptoms (memory difficulties, brain fog, depression), and emotional changes persist long after finasteride discontinuation. This cluster of persistent adverse effects is termed post-finasteride syndrome (PFS). The FDA has updated finasteride labeling to acknowledge reports of persistent sexual dysfunction after stopping the drug. PFS is recognized as a real clinical phenomenon by the FDA, though its mechanism remains incompletely characterized. Proposed mechanisms include alterations in neurosteroid production, epigenetic changes to androgen receptor expression, and disruption of the neuroendocrine axis. Patients experiencing persistent symptoms after stopping finasteride should consult a healthcare provider.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Alpha-1 Blockers (tamsulosin, doxazosin, terazosin) | Combination therapy (finasteride + alpha blocker) is a standard, guideline-recommended approach for BPH — the two drug classes address different components of obstruction (static vs. dynamic). Not an adverse interaction but an intentional therapeutic combination. | Beneficial combination — no adverse pharmacokinetic interaction; monitor blood pressure |
| CYP3A4 Inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin) | Finasteride is metabolized by CYP3A4. Inhibitors may increase finasteride plasma concentrations. Clinical significance is generally low because finasteride has a wide therapeutic margin. | Low — generally not clinically significant; no dose adjustment typically required |
| PSA Assay Interpretation (not a drug interaction, but critical) | Finasteride suppresses PSA by ~50%, creating false-low PSA results on prostate cancer screening. Clinicians must apply a 2× correction factor to measured PSA values in finasteride-treated patients. | Critical for clinical interpretation — failure to correct can delay prostate cancer diagnosis |
| Warfarin | No clinically significant pharmacokinetic interaction reported. Concurrent use does not require INR adjustment in most patients. | Low — routine monitoring unchanged |
Warnings & Contraindications
Contraindications
- Women who are pregnant or may become pregnant (teratogenic — causes abnormal male fetal genital development)
- Children (not approved for pediatric use)
- Hypersensitivity to finasteride or any excipient
Pregnancy and Teratogenicity
Finasteride is classified as FDA Pregnancy Category X — it causes fetal harm and is absolutely contraindicated in pregnancy. Specifically, it causes abnormal development of male external genitalia (hypospadias, ambiguous genitalia) in fetuses exposed in utero. DHT is essential for normal masculinization of the male fetus; finasteride interrupts this process. Women who are or may become pregnant must not handle crushed or broken finasteride tablets because the drug is absorbed through skin. Intact, coated tablets that are not broken or crushed do not present the same dermal absorption risk, but avoidance of any contact is the safest approach.
Prostate Cancer Risk and PSA Effects
The Prostate Cancer Prevention Trial (PCPT) found that finasteride reduced the overall incidence of prostate cancer by approximately 25%, but appeared to increase the proportion of high-grade (Gleason score 7–10) cancers detected among those who did develop prostate cancer. The FDA requires labeling to discuss this finding. Current interpretation holds that this may be partly a detection artifact — finasteride shrinks the prostate and concentrates high-grade cancers that are detectable by biopsy — but the finding warrants discussion between clinicians and patients. Finasteride does not treat prostate cancer.
Because finasteride reduces PSA by approximately 50%, men on finasteride should have a baseline PSA established before or early in treatment, and subsequent values should be doubled for comparison against normal ranges. Any confirmed increase in PSA while on finasteride warrants evaluation even if the absolute value remains within the normal range.
Male Fertility
DHT plays a role in spermatogenesis and sperm function. Finasteride can reduce sperm count, motility, and morphology in some men, potentially affecting fertility. Men planning to father children should discuss finasteride use with their prescriber. These effects are generally reversible upon discontinuation, though reversal timelines vary.
Check finasteride for interactions with your other medications.
Check Drug Interactions →Frequently Asked Questions
Does finasteride affect PSA prostate cancer screening?
Yes — this is a critical clinical issue. Finasteride reduces serum PSA levels by approximately 50% after six months of treatment. Because PSA is used to screen for prostate cancer, finasteride use can mask a PSA elevation that would otherwise prompt further investigation. To interpret PSA correctly in patients taking finasteride, clinicians must double the observed PSA value to estimate what it would be without the drug. Patients should inform all healthcare providers about finasteride use before any prostate cancer screening.
Are the sexual side effects of finasteride permanent?
For most patients who experience sexual side effects — decreased libido, erectile dysfunction, reduced ejaculatory volume — symptoms resolve after discontinuing finasteride. However, a subset of patients report that sexual dysfunction, cognitive changes (brain fog), and emotional symptoms persist indefinitely after stopping the drug. This cluster of persistent symptoms is called post-finasteride syndrome (PFS). The FDA has required labeling updates acknowledging persistent sexual dysfunction. The mechanism of PFS is not fully understood; proposed theories involve neurosteroid alteration, epigenetic changes, and altered androgen receptor signaling.
How long does finasteride take to work for hair loss?
Finasteride for androgenetic alopecia requires consistent daily use for at least 3–6 months before meaningful changes become apparent, and full assessment of efficacy typically requires 12 months of treatment. The drug first slows or halts progression of hair loss before stimulating regrowth in some patients. If finasteride is stopped at any point, the underlying DHT-driven hair loss process resumes, and hair preserved or regained during treatment is typically lost within 6–12 months of discontinuation.
Why can't women who are or may become pregnant touch finasteride tablets?
Finasteride is teratogenic to male fetuses. DHT is essential for normal development of external male genitalia in utero; finasteride inhibits its production, which can cause abnormal genital development (ambiguous genitalia or hypospadias) in a male fetus. Even transdermal absorption through skin contact with a crushed or broken tablet is sufficient to pose a risk. Finasteride tablets are film-coated specifically to limit casual contact exposure. Pregnant women and women who may become pregnant must avoid all contact with broken or crushed finasteride tablets.